Enterprise Value
-116.5M
Cash
205.8M
Avg Qtr Burn
-12.36M
Short % of Float
2.25%
Insider Ownership
10.18%
Institutional Own.
61.89%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
TEMBEXA (brincidofovir) Details Smallpox | Approved Quarterly sales | |
ONC201 Details Cancer, Glioma, Brain tumor | Phase 3 Data readout | |
ONC206 Details Brain tumor, Solid tumor/s, Glioblastoma | Phase 1 Data readout | |
Dociparstat sodium (DSTAT) Details Cancer, Acute myeloid leukemia | Failed Discontinued | |
Dociparstat sodium (DSTAT) Details Infectious disease, COVID-19 | Failed Discontinued |